GlassScriptPhysician profile
David H Kim
NPI 1396705661
$1,541.37
in general payments reported to CMS, 2019-2025
29 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $148 · 2021: $24.51 · 2022: $70.66 · 2023: $196 · 2024: $424 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.59 | 2019-2024 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $147.33 | 2019 | |
| Glaxosmithkline, LLC. | $113.07 | 2023-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $104.52 | 2024 | |
| Exact Sciences Corporation | $79.73 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $70.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $69.26 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $66.37 | 2019-2024 | |
| Lilly USA, LLC | $62.48 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $58.80 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.33 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $38.43 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $38.27 | 2024-2025 | Gemtesa |
| Pfizer INC. | $37.62 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $32.02 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $26.01 | 2020 | |
| Allergan, INC. | $23.81 | 2019 | |
| Digestive Care, INC. | $20.64 | 2024 | Pertzye |
| Radius Health, INC. | $19.04 | 2019 | |
| Lundbeck LLC | $18.23 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $15.89 | 2019 | |
| Intra-Sana Laboratories | $15.23 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $13.69 | 2019 | |
| Merck Sharp & Dohme LLC | $12.20 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.